Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics

“… 36 Recently, bimekizumab, an antibody targeting both IL-17A and IL-17F, has completed phase 3 trials. 63 , 64 The clinical response to bimekizumab was rapid and substantial with 77% of subjects achieving PASI75 at week 4 and 91% of subjects achieving PASI90 at week 12. 63 Whether the dual inhibition of IL-17A and IL-17F (bimekizumab) is superior to inhibition of IL-17A (secukinumab) is currently being investigated in a head-to-head comparison in a phase 3 clinical trial (NCT03536884).…”

From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment

“…Results from a phase III clinical trial comparing bimekizumab with adalimumab in moderate-to-severe plaque psoriasis patients have shown that bimekizumab was superior to adalimumab in reducing symptoms and signs of plaque psoriasis, but had a higher frequency of oral candidiasis and diarrhea [108]. Two more phase III studies with an active comparator have shown that bimekizumab is more effective than ustekinumab [109] and secukinumab [110].…”

Bimekizumab: the new drug in the biologics armamentarium for psoriasis

“… 13 In phase I and II clinical trials of psoriasis, bimekizumab has shown promising results leading to the continuation of its development programme. Four phase III studies were conducted to compare bimekizumab with placebo ustekinumab (BE VIVID, NCT03370133 16 ), (BE READY, NCT03410992 17 ) adalimumab (BE SURE, NCT03412747 18 ), and secukinumab (BE RADIANT, NCT03536884 19 ). These trials demonstrated the superiority of bimekizumab over placebo and ustekinumab, adalimumab and secukinumab.…”

“…In the BE VIVID study, 16 the safety and efficacy of bimekizumab were compared, over 52 weeks, with ustekinumab and placebo. At week 16, 85% of patients on bimekizumab achieved a 90% reduction in the Psoriasis Area and Severity Index (PASI90), whilst only 50% of patients taking ustekinumab and 4% of patients on placebo achieved the same result ( p <0.0001 for both comparisons); an Investigator’s Global Assessment (IGA) score of 0/1 was obtained in a significantly higher percentage in patients treated with bimekizumab than with ustekinumab and placebo (84%, 53% and 5%, respectively; p <0.0001).…”

“…Regarding the safety profile in both studies, it was found that, in the BE VIVID study, 6% of patients receiving bimekizumab had serious treatment-emergent adverse events (TEAEs) versus 8% in the ustekinumab group. 16 In the BE READY study, TEAEs occurred in 74%, 77% and 69% of patients treated with bimekizumab 320 mg Q4W, bimekizumab 320 mg Q8W and placebo, respectively; of these, severe TEAEs were considered in 5%, 3% and 4% of patients with bimekizumab 320 mg Q4W, bimekizumab 320 mg Q8W and placebo, respectively. 17 …”